as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹459.25
Change
+5.1 (1.12%)
Open
₹456.3
Prev. Close
₹454.15
Day High
₹460.0
Day Low
₹450.05
Volume Analysis
Traded
557,235
Delivered
413,137
Delivery %
74.14%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (2)
- •Low return on equity (4.89%)
- •Promoter holding is falling
Opportunities (1)
- •Strong 3-year revenue growth (19.2%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹472.76 | ₹466.38 | ₹462.81 | ₹456.43 | ₹452.86 | ₹446.48 | ₹442.91 |
| Fibonacci | ₹466.38 | ₹462.58 | ₹460.23 | ₹456.43 | ₹452.63 | ₹450.28 | ₹446.48 |
| Camarilla | ₹461.99 | ₹461.07 | ₹460.16 | ₹456.43 | ₹458.34 | ₹457.43 | ₹456.51 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-12.27%
1 Week
-0.26%
1 Month
+2.08%
3 Months
+0.68%
6 Months
+47.22%
1 Year
-47.17%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹103.64
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
1.61%
Net margin 2.75% × asset turnover 0.4x × equity multiplier 1.46x
Company Overview
Sector
Healthcare
Market Cap
₹17,290 Cr
P/E (TTM)
161.0
ROE
4.89%
Book Value
₹102.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Cohance Lifesciences Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 53/100. The strongest factor is Financial Strength (100/100), while Valuation (22/100) is the weakest area to weigh before deciding. Notably: Low return on equity (4.89%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
53/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has a low return on equity of 10.6% over last 3 years.
- −Promoters have pledged 94.6% of their holding.
- −Debtor days have increased from 88.0 to 110 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
USFDA inspected Jaggaiahpet API facility from 14-19 Sep 2026; issued Form 483 with five observations.
Cohance remitted USD 10 million to subscribe 188,680 CCPS in subsidiary NJ Bio Inc.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 348 | 231 | 220 | 253 | 488 | 604 | 676 | 840 | 549 | 556 | 545 | 619 | 422 |
| Expenses + | 181 | 133 | 154 | 180 | 363 | 398 | 439 | 611 | 437 | 435 | 449 | 520 | 421 |
| Operating Profit | 167 | 98 | 66 | 73 | 125 | 205 | 237 | 229 | 112 | 121 | 95 | 99 | 1 |
| OPM % | 48.0% | 42.0% | 30.0% | 29.0% | 26.0% | 34.0% | 35.0% | 27.0% | 20.0% | 22.0% | 18.0% | 16.0% | 0.3% |
| Other Income + | 11 | 20 | 14 | 17 | 19 | 16 | 22 | -4 | 6 | 16 | 1 | -18 | 12 |
| Interest | 1 | 0 | 2 | 2 | 10 | 10 | 11 | 10 | 10 | 9 | 9 | 9 | 7 |
| Depreciation | 13 | 12 | 13 | 17 | 31 | 38 | 44 | 54 | 45 | 44 | 47 | 51 | 50 |
| Profit before tax | 164 | 105 | 65 | 71 | 103 | 174 | 205 | 161 | 63 | 84 | 41 | 20 | -43 |
| Tax % | 26.0% | 25.0% | 29.0% | 25.0% | 27.0% | 21.0% | 25.0% | 27.0% | 26.0% | 21.0% | 29.0% | 58.0% | 5.0% |
| Net Profit + | 121 | 80 | 47 | 53 | 75 | 138 | 153 | 117 | 46 | 66 | 29 | 8 | -45 |
| EPS in Rs | 5 | 3 | 2 | 2 | 3 | 5 | 6 | 5 | 1 | 2 | 1 | 1 | -1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 2,608 | 2,269 | 2,142 |
| Expenses + | 206 | 449 | 567 | 738 | 766 | 645 | 1,811 | 1,841 | 1,825 |
| Operating Profit | 172 | 385 | 443 | 582 | 574 | 406 | 797 | 427 | 316 |
| OPM % | 45.0% | 46.0% | 44.0% | 44.0% | 43.0% | 39.0% | 31.0% | 19.0% | 15.0% |
| Other Income + | 1 | 66 | 68 | 133 | 46 | 62 | 53 | 4 | 11 |
| Interest | 3 | 23 | 12 | 9 | 13 | 7 | 41 | 37 | 34 |
| Depreciation | 12 | 24 | 32 | 39 | 48 | 55 | 167 | 187 | 192 |
| Profit before tax | 158 | 405 | 468 | 668 | 560 | 406 | 643 | 207 | 101 |
| Tax % | 31.0% | 22.0% | 23.0% | 32.0% | 27.0% | 26.0% | 25.0% | 27.0% | — |
| Net Profit + | 109 | 317 | 362 | 454 | 411 | 300 | 484 | 150 | 59 |
| EPS in Rs | — | 12 | 14 | 18 | 16 | 12 | 19 | 5 | 3 |
| Dividend Payout % | 0.0% | 20.0% | 14.0% | 28.0% | 37.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 3,623 | 3,873 |
| Borrowings + | 83 | 186 | 143 | 97 | 70 | 65 | 486 | 400 |
| Other Liabilities + | 123 | 142 | 151 | 205 | 160 | 138 | 1,346 | 1,415 |
| Total Liabilities | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 5,480 | 5,727 |
| Fixed Assets + | 271 | 357 | 441 | 534 | 663 | 670 | 3,107 | 3,369 |
| CWIP | 111 | 102 | 96 | 30 | 165 | 179 | 334 | 178 |
| Investments | 7 | 338 | 542 | 598 | 536 | 904 | 337 | 529 |
| Other Assets + | 394 | 376 | 395 | 667 | 601 | 501 | 1,702 | 1,652 |
| Total Assets | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 5,480 | 5,727 |
| Equity Capital | 0 | 13 | 25 | 25 | 25 | 25 | 25 | 38 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 50 | 407 | 383 | 330 | 457 | 358 | 673 | 368 |
| Cash from Investing Activity + | -65 | -413 | -311 | -136 | -195 | -362 | -388 | -251 |
| Cash from Financing Activity + | 26 | 7 | -76 | -156 | -242 | -14 | -327 | -165 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | -42 | -48 |
| CFO/OP | 49 | 128 | 111 | 88 | 105 | 115 | 107 | 102 |
| Free Cash Flow | -6 | 304 | 272 | 255 | 171 | 307 | 357 | 169 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 15.85% | 13.93% | 23.11% | 22.67% | 22.26% | 22.37% | 22.24% | 14.95% | 15.16% | 14.91% | 15.11% | 15.92% |
| Promoters | 60.0% | 60.0% | 50.1% | 50.1% | 50.1% | 50.1% | 50.1% | 66.41% | 57.49% | 57.49% | 57.49% | 57.49% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| FII | 10.01% | 10.14% | 9.54% | 9.8% | 10.7% | 10.84% | 11.05% | 7.23% | 6.51% | 6.01% | 5.59% | 6.5% |
| DII | 14.13% | 15.94% | 17.24% | 17.42% | 16.95% | 16.67% | 16.6% | 11.4% | 20.81% | 21.57% | 21.79% | 20.09% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Cohance Lifesciences Ltd (this stock) | 17,290 | 161.0 | 4.43 | 4.89% |
| Jubilant Pharmova Ltd | 17,118 | 44.1 | 2.41 | 6.53% |
| Poly Medicure Limited | 17,479 | 54.6 | 5.63 | 9.02% |
| Eris Lifesciences Limited | 17,618 | 26.9 | 4.5 | 18.7% |
| Alivus Life Sciences Ltd | 16,820 | 47.8 | — | — |
| Alembic Pharma Ltd | 16,708 | 22.4 | 2.94 | 13.4% |
| Pfizer Ltd | 18,303 | 119.0 | 13.25 | 19.8% |
Which Mutual Funds Hold Cohance Lifesciences Ltd?
Frequently Asked Questions about Cohance Lifesciences Ltd
Cohance Lifesciences Ltd (COHANCE) closed at ₹459.25 on NSE on 25 September 2026, up 5.1 (1.12%) from the previous close.
Cohance Lifesciences Ltd trades on the NSE (National Stock Exchange of India) under the symbol COHANCE.
Cohance Lifesciences Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 161.0.
Cohance Lifesciences Ltd has a dividend yield of 0.0%.
Cohance Lifesciences Ltd's 52-week high is ₹918.0 and its 52-week low is ₹267.0.
Cohance Lifesciences Ltd has a market capitalisation of ₹17,290 crore.
Cohance Lifesciences Ltd has a TopFund Quality Score of 53/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Cohance Lifesciences Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.